RxDoctor Payments DataLook up a doctor →

Miguel Diaz, MD

Interventional Cardiology · Hialeah, FLNPI 1013118322

Payments from drug & device makers

$497,335in general payments, 2019–2025

Across 908 payments — averaging $547.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Chiesi USA, Inc.$178K
  • Amgen$112K
  • AstraZeneca$79K
  • Abbott$53K
  • Shockwave Medical, Inc$34K
  • Boston Scientific$12K
  • plus $30K from 52 others

What the payments were for

  • Consulting fees$9,6903%
  • Speaking & faculty fees$328,16686%
  • Travel & lodging$10,4043%
  • Food & beverage$35,0019%
  • Education$1740%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$497,335 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$69,850
Medicare patients
121
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$137,867
EntrestoSacubitril/Valsartan119$128,002
Repatha SureclickEvolocumab163$121,138
FarxigaDapagliflozin Propanediol70$67,812
BrilintaTicagrelor91$62,236
XareltoRivaroxaban56$54,378
MultaqDronedarone Hcl11$23,000
VascepaIcosapent Ethyl18$11,380
Praluent PenAlirocumab16$8,064
EdarbyclorAzilsartan Med/Chlorthalidone17$5,566
Amiodarone Hcl41$2,999
Metoprolol Succinate197$1,363
Ranolazine ErRanolazine18$1,239
Atorvastatin Calcium183$990
Rosuvastatin Calcium83$930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$596$137,867118 claims
AstraZenecaFarxiga, Brilinta$78,726$130,048161 claims
NovartisEntresto$845$128,002119 claims
Johnson & JohnsonXarelto$116$54,37856 claims
Sanofi-aventis U.S. LLCMultaq$145$23,00011 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$19$5,56617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →